Biotech
Columbia Laboratories Registered Direct Offering (NASDAQ:CBRX)
Columbia Laboratories, Inc. (NASDAQ:CBRX), a company that is into the development, manufacturing and commercialization of pharmaceutical products has successfully raised around $11,772,000 in gross proceeds through the sale of 10,900,000 shares of its common stock and warrants to purchase 5,450,000 shares of its common stock in a registered direct offering.
Continue reading...Celera’s New Agreement With Laboratory Service (NASDAQ:CRA)
29 October 2009 – 9:23 am PDT
Comments Off
Berkeley HeartLab, a subsidiary of Celera Corporation (NASDAQ:CRA) announced today that they have entered into a collaborative agreements with Geisinger Medical Center and Proven Diagnostics, a clinical laboratory service launched by Geisinger Health System recently.
Continue reading...Theravance’s New Horizon (THRX, GSK)
28 October 2009 – 7:00 am PDT
Comments Off
Theravance, Inc. (NASDAQ:THRX) today announced that they have commence Phase 3 of Horizon programme with GlaxoSmithKline plc (ADR) (NYSE:GSK)Â to develop a next generation treatment for COPD.
Continue reading...ZymoGenetics receives milestone payment
28 October 2009 – 6:50 am PDT
Comments Off
ZymoGenetics, Inc. (NASDAQ:ZGEN) announced the initiation of a Phase 2 clinical trial of PEG-Interferon lambda (IL-29) and ribavirin in treatment naive patients with chronic hepatitis C virus (HCV) infection.
Continue reading...Arena Pharmaceuticals New Data (NASDAQ:ARNA)
28 October 2009 – 6:40 am PDT
Comments Off
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced new findings today, adding to the previously announced top line BLOSSOM data that showed highly significant weight loss with lorcaserin over one year of treatment in about four thousand patients.
Continue reading...Orexigen’s New Data (NASDAQ:OREX)
28 October 2009 – 6:30 am PDT
Comments Off
Orexigen Therapeutics, Inc. (NASDAQ:OREX) has announced and presented their new data from the COR diabetes trials for Contrave to expand on top line results announced in July this year.
Continue reading...GSK Arzerra Approved (NYSE:GSK)
27 October 2009 – 10:40 am PDT
Comments Off
On Monday morning, the Food and Drug Administration panel approved Arzerra, a leukemia treatment that will be marketed and commercialized by GlaxoSmithKline Plc (ADR) (NYSE:GSK).
Continue reading...Sanofi drags Hospira and Apotex (NYSE:SNY)
27 October 2009 – 9:54 am PDT
Comments Off
Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere.
Continue reading...Lifeline Estimates Six Months For FDA Response (PINK:LLBO)
26 October 2009 – 12:54 pm PDT
Lifeline Biotech (Public, PINK:LLBO) reported today about the status of their First Warning Systemâ„¢ 510(k) FDA application. The consulting firm, Lifeline Biotech used to submit the FDA application, advised that the “FDA is running anywhere from 30 to 60 days past the normal time expected to provide a response”.
Continue reading...Novo Nordisk races ahead (NYSE:NVO)
26 October 2009 – 7:30 am PDT
Comments Off
Novo Nordisk A/S (ADR) (NYSE:NVO) has made an announcement that their diabetes treatment Liraglutide cuts weight and reduces health risks in obese non-diabetics.
Continue reading...
29 October 2009 – 9:27 am PDT
Comments Off